Opinion

Video

Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer

Author(s):

Stephen J. Freedland, MDEleni Efstathiou, MD, PhD

The panel of prostate cancer experts explores risk stratification methodologies and prognostic markers for castration-sensitive prostate cancer, emphasizing crucial factors that influence patient categorization and treatment decisions.

  1. Dr. Efstathiou asks Dr. Freedland: What are the key factors you consider in risk stratification of your patients? What clinical characteristics and existing biomarkers help guide your assessment?
  2. What promising biomarkers have emerged that may help detect early signs of prostate cancer progression? (Logan Cancers 2023, Kumaraswamy JCI Insight 2023, please highlight any others) 

Related Videos
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
5 KOLs are featured in this program
5 KOLs are featured in this program
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
2 KOLs are featured in this panel.
Related Content
Marc-Oliver Grimm, MD, professor, chairman, Department of Urology, Jena University Hospital
June 25th 2024

ARASENS Trial Demonstrates Significant Survival Benefits With Triplet Therapy in mHSPC

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Michael J. Morris, MD
June 10th 2024

JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Fernando Cotait Maluf, MD
June 7th 2024

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

Ronald C. Chen, MD, MPH, FASCO, FASTRO
June 6th 2024

Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate Cancer